Phase 3 HAE Prophylaxis Data Coming in 3Q26; "Cantor Catalysts" Webinar Recap

Research evidence excerpt

Phase 3 HAE Prophylaxis Data Coming in 3Q26; "Cantor Catalysts" Webinar Recap

June 29, 2026

This material is being presented solely as institutional communications and is not meant to be viewed as a complete fundamental analysis of any security.

This material may offer recommendations and strategies which are shorter term in nature. If the material contains analysis, it may be narrowly focused, and

may be based either purely on quantitative models or other unique factors such as market supply/demand factors surrounding potential market moving

events. When making an investment decision this information should be viewed as just one factor in your investment decision process. Past performance

should not be taken as an indication or guarantee of future results.

The United States of America: US Research is produced and distributed in the US by Cantor Fitzgerald & Co (“CF&Co.”), which is an SEC registered broker-

dealer and a member of FINRA. Research prepared by affiliates of CF&Co. may also be distributed in the United States by CF&Co. directly, or by affiliates

exclusively to Major US Institutional Investors (as such term is defined in Rule 15a-6 under the Securities Exchange Act of 1934, as amended) and is not

intended for the use of any person or entity that is not a major institutional investor. Major US Institutional Investors receiving this report and wishing to

effect transactions in securities discussed in this report must do so through CF&Co.

For Research prepared by Affiliates of CF&Co., CF&Co. accepts responsibility for the content of Research Reports prepared by affiliates when distributed to

US persons. Although it has accepted responsibility for the content when distributed to US investors, CF&Co. did not contribute to the preparation of those